Digest Network Come funziona
Network
/
Società
F.
Non verificato

F. Hoffmann-La Roche Ltd

Di cosa scriviamo

Annunci EconomiciFarmaceuticaPubblicità/Marketing/Media/Comunicazione

140 comunicati stampa

Guarda tutti i comunicati
17/06/2026
Farmaceutica
Annunci Economici
FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
12/06/2026
Farmaceutica
Annunci Economici
Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
10/06/2026
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
07/06/2026
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
01/06/2026
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
31/05/2026
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
26/05/2026
Farmaceutica
Annunci Economici
Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
18/05/2026
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
11/05/2026
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
06/05/2026
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0